H.B. Fuller is facing renewed pressure to reshape its portfolio after activist investor Ancora Holdings proposed acquiring the company’s Building Adhesive Solutions business for as much as $1.2 billion in cash.
Ancora announced the proposal on August 12, 2026, asking H.B. Fuller’s board to formally explore a transaction involving the unit.
At this stage, the proposal remains an unsolicited acquisition offer rather than a signed transaction.
In a letter to H.B. Fuller’s board, Ancora described the potential sale as beneficial to both the company and its shareholders and said it was prepared to enter into a confidentiality agreement and begin due diligence immediately.
Ancora owns more than 2% of H.B. Fuller.
Reuters also reported that the investment firm has been considering a proxy fight to gain influence or control over the company’s board, turning the acquisition proposal into part of a broader corporate-governance dispute.
The two sides had already been in contact.
Ancora said it privately re-engaged with H.B. Fuller’s chief executive and chairman in early July over a potential deal but did not receive a substantive response.
The public proposal effectively moves those discussions from private engagement into the market spotlight.
The Building Adhesive Solutions business serves construction markets with adhesives, sealants and related products.
Construction adhesives represent a large market, but the sector is fragmented and includes numerous regional suppliers.
Compared with medical adhesives, advanced electronics materials and certain high-performance industrial bonding technologies, conventional construction products can face stronger price competition and lower margins.
That distinction sits at the center of Ancora’s argument.
The investor believes that selling the business would allow H.B. Fuller to exit a lower-margin segment in a highly fragmented market while concentrating capital and management attention on higher-value businesses.
The proposal is closely linked to another major deal already underway at H.B. Fuller.
Earlier this year, the company agreed to acquire British medical-products supplier Advanced Medical Solutions Group in a transaction valued at around £715 million including debt, or approximately $967 million using the exchange rate cited by Reuters on August 12.
Advanced Medical Solutions operates in wound care, surgical closure and medical materials.
Those markets generally involve higher regulatory barriers, longer customer qualification processes and greater product differentiation than conventional construction adhesives.
That makes them more consistent with the strategy many specialty chemical companies are pursuing: reducing exposure to commoditized applications while increasing their presence in technically demanding end markets.
Ancora had previously criticized H.B. Fuller’s acquisition of Advanced Medical Solutions, describing the transaction as poor capital allocation.
Its current argument is different.
Since H.B. Fuller is proceeding with the medical expansion, Ancora says the company should sell Building Adhesive Solutions, release capital and concentrate on integrating AMS.
The $1.2 billion proposal is therefore about more than selling one division. It raises a broader question about what type of specialty materials company H.B. Fuller should become.
H.B. Fuller has long operated as one of the world’s larger pure-play adhesive producers, serving packaging, hygiene, automotive, construction, woodworking, electronics and other industrial markets.
That diversified structure reduces exposure to any single end market, but it also means that different businesses carry very different growth and margin profiles.
Activist investors typically push companies to dispose of lower-growth or lower-return assets and redirect capital toward businesses with stronger strategic differentiation.
That strategy is becoming increasingly visible across the chemical sector.
As overall industry growth slows, investors are paying closer attention to portfolio quality rather than simply revenue scale.
Assets serving medical, electronics, semiconductor and aerospace markets often command higher valuations, while construction, basic industrial and more commoditized specialty products face greater pressure for divestment.
Ancora has also recently pressed chemical producer Ashland to consider a sale, showing that similar portfolio-restructuring arguments are being applied across the specialty chemicals industry.
For H.B. Fuller, accepting a transaction could generate significant cash proceeds and reduce exposure to construction cycles.
But a divestment would also carry risks.
Building adhesives provide scale and recurring cash flow, while selling the business would reduce group revenue and increase dependence on medical and other higher-value end markets.
Key details also remain unknown, including the unit’s standalone profitability, the precise transaction structure and how Ancora would finance a purchase of up to $1.2 billion.
For that reason, the situation should still be described as a strategic acquisition proposal rather than an agreed divestment.
The market will now watch whether H.B. Fuller opens a formal strategic review, allows Ancora to conduct due diligence or attracts competing bidders.
If the transaction eventually moves forward, it could become one of the most significant portfolio changes in H.B. Fuller’s recent history and accelerate the company’s shift toward medical and higher-performance materials.
More broadly, the dispute reflects growing capital-allocation pressure across specialty chemicals.
Investors are increasingly demanding that companies prove the margin, growth and strategic value of every major business in their portfolios rather than relying on the “specialty chemicals” label alone.
